全文获取类型
收费全文 | 1574篇 |
免费 | 74篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 79篇 |
妇产科学 | 24篇 |
基础医学 | 184篇 |
口腔科学 | 22篇 |
临床医学 | 172篇 |
内科学 | 384篇 |
皮肤病学 | 53篇 |
神经病学 | 40篇 |
特种医学 | 312篇 |
外科学 | 183篇 |
综合类 | 26篇 |
预防医学 | 59篇 |
眼科学 | 6篇 |
药学 | 69篇 |
中国医学 | 2篇 |
肿瘤学 | 90篇 |
出版年
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 19篇 |
2020年 | 14篇 |
2019年 | 12篇 |
2018年 | 26篇 |
2017年 | 6篇 |
2016年 | 15篇 |
2015年 | 21篇 |
2014年 | 29篇 |
2013年 | 52篇 |
2012年 | 56篇 |
2011年 | 30篇 |
2010年 | 50篇 |
2009年 | 71篇 |
2008年 | 49篇 |
2007年 | 80篇 |
2006年 | 39篇 |
2005年 | 38篇 |
2004年 | 38篇 |
2003年 | 39篇 |
2002年 | 25篇 |
2001年 | 31篇 |
2000年 | 34篇 |
1999年 | 36篇 |
1998年 | 84篇 |
1997年 | 86篇 |
1996年 | 107篇 |
1995年 | 64篇 |
1994年 | 60篇 |
1993年 | 54篇 |
1992年 | 27篇 |
1991年 | 23篇 |
1990年 | 32篇 |
1989年 | 46篇 |
1988年 | 44篇 |
1987年 | 37篇 |
1986年 | 44篇 |
1985年 | 44篇 |
1984年 | 10篇 |
1983年 | 16篇 |
1982年 | 14篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1976年 | 16篇 |
1975年 | 13篇 |
1970年 | 2篇 |
排序方式: 共有1706条查询结果,搜索用时 15 毫秒
91.
92.
JC Cole P Lin & MFT Rupnow 《Cephalalgia : an international journal of headache》2009,29(11):1180-1187
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention ( n = 916), as well as from the QualityMetric National Headache Survey ( n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses. 相似文献
93.
94.
95.
96.
97.
Three recent publications have reported the development of erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and sodium phenytoin. Some authors have recommended that patients receiving whole brain radiation therapy and who have had seizures should not be prescribed phenytoin but an alternative anticonvulsant. This article reviews the current literature pertaining to the development of this potentially lethal complication in patients receiving whole brain radiation and phenytoin, with reference to the single recorded case of Stevens-Johnson syndrome in a patient receiving cranial irradiation and phenytoin in Auckland, New Zealand. While the clinical picture in the 16 patients reported in the literature and the current case report differed from the classical form of erythema multiforme, a similar pattern of presentation and outcome appeared in all patients reviewed, suggesting that the combination of phenytoin, cranial irradiation and the gradual reduction of concomitant steroids seem to lead to the development of erythema multiforme and/or Stevens-Johnson syndrome. The data presented, although sparse, suggest that phenytoin should not be prescribed in patients receiving cranial irradiation. 相似文献
98.
99.
100.